•H.C. Wainwright reiterated a Buy rating and $150 price target for Incyte following a review of clinical trial data for its experimental cancer drug INCB161734.
•Incyte reported strong Q2 2026 results with revenue of $1.67 billion, representing a 37.7% year-over-year increase.
•The company raised its full-year sales guidance after beating analyst EPS expectations with a reported $3.09.
